W. Clay Gustafson

Twitter (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

27h-index5.1kcitations181works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(77), Cancer Research and Treatments(61), Neuroblastoma Research and Treatments(56), ATP Synthase and ATPases Research(29), Protein Degradation and Inhibitors(24)

Publications178 total

Supplementary Tables1 from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
2025Open Access
Suppl Figures 1 from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
2025Open Access
EXTH-117. Bitopic inhibitors of mTORC1 cooperate with inhibitors of mitogen-activated protein kinase kinase to drive cytotoxicity in glioblastoma
Neuro-Oncology·2025Open Access
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Clinical Cancer Research·2025· 2 citedOpen Access
Correction: Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Cancer Discovery·2025Open Access
Supplementary Table S5 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S8 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 4 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S4 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 3 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 6 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Method from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 5 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 7 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 2 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Figure 1 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S7 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S3 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
Supplementary Table S1 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2025Open Access
page 1 of 9Next →

Frequent Co-authors

William A. Weiss(23), Katherine K. Matthay(9), Nicole Nasholm(7), Kevan M. Shokat(6), Mallika Singh(6), Erin A. Nekritz(5), Justin Meyerowitz(5), Alan P. Fields(5), Jun Qi(4), Yvan H. Chanthery(4), James E. Bradner(4), Kimberly Stegmaier(4), Justin Chen(4), Zhican Wang(4), Elise Charron(3), Gabriela Alexe(3), Cyril H. Benes(3), Erin F. Simonds(3), Christine Cheng(3), Robyn A. Wong(3)